In this regard, ongoing trials are exploring combinations of different immunotherapy agents and chemotherapy regimens to enhance the host immune response in the neoadjuvant setting in triple negative and HER2-positive BC [33,34,35]. The gene discussed is ERBB2; the disease is breast cancer.